Navigation Links
BioSpecifics Technologies Corp. Announces Top-line Data from Phase 2 Trial of CCH for Canine Lipoma
Date:12/23/2013

h was not statistically significant. The percent change at 90 days in mean visible surface area measured by caliper showed a difference of -24.18% (p=0.09), which approached statistical significance. Among those dogs whose lipomas decreased by 50%, the results achieved statistical significance and showed that the visible surface area as measured by caliper decreased by 50% or more in 47.4% of CCH-treated dogs (9 out of 19) versus 5.9% of placebo-treated dogs (1 out of 17), with a p-value of 0.0084. A questionnaire administered to pet owners, while blinded to the study, showed 84.2% satisfaction with the results of CCH treatment versus 33.4% satisfaction with the placebo results (p=0.005).

There were no drug-related serious adverse events reported during the trial. The most frequent treatment-related adverse events were local injection site reactions including bruising, injection site swelling, injection site pain and injection site edema. These adverse events are consistent with those seen previously in clinical experience in humans.

"We believe that this minimally-invasive approach of CCH for the treatment of canine lipomas has the potential to be a very important development in veterinary medicine," said Dr. Sarit Dhupa, Director of Surgery at California Veterinary Specialists and Lead Investigator on the Chien-804 trial. "At present, the standard of care therapy available to treat canine lipomas is invasive surgery. This clearly can result in higher morbidity, a greater risk of mortality particularly to older pets and puts a greater financial burden on pet owners. A minimally-invasive option would revolutionize the way we treat this disease."

BioSpecifics' strategic partner Auxilium Pharmaceuticals, Inc. (Auxilium) has the option to exclusively license development and marketing rights to the canine lipoma indication, which would trigger an opt-in payment and potential future milestone and roya
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
2. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
5. BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
6. BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. BioSpecifics Technologies Corp. Announces Partnership between Auxilium and Swedish Orphan Biovitrum AB for XIAPEX in Eurasia and Africa
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2013 Financial Results on Tuesday, November 12, 2013
9. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
10. UV Flu Technologies Expands Its International Footprint
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Nine field days to promote practices that ... by the Soil Health Partnership , the field days will demonstrate how changing ... increasing farm productivity and income. , Brent Bible has practiced no-till farming and planted ...
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... pumps to its comprehensive line of analytical laboratory equipment. With optimized features, such ... pumps provide a chemically resistant and maintenance-free solution for a broad range of ...
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... , , , ... (OTC Bulletin Board: IAGX), an innovator of scientifically tested, natural-based, ... of Research & Development, was interviewed by Pimm Fox on ... the bioceutical business of Imagenetix outlining the science behind its ...
... to also Raise $7.5 Million in Non-Dilutive Financing from, ... 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) ... a definitive agreement, subject to shareholder and regulatory approvals, whereby ... and merger to continue as a publicly-traded entity to be ...
... , , SAN DIEGO, ... Ip, Chair Professor of the Department of Biochemistry and Director ... Science and Technology (HKUST), has joined their scientific advisory board. ... and recipient of China,s highest honor in the natural sciences, ...
Cached Biology Technology:Imagenetix, Inc. Announces Interview With Bloomberg Radio 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 3Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 4Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 5Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 6Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 7Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 8Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 9Professor Nancy Ip Joins aTyr Pharma's Scientific Advisory Board 2
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... University have created a blueprint for artificial cells that ... they mimic and could one day be used to ... with the question of whether an artificial version of ... could be designed as a potential power source. ...
... investigating the rice genome has been developed by researchers ... plant pathology. The inexpensive, publicly-available rice DNA microarray covers ... Details are published this week in the open-access journal ... as humans or rice plants, each cell type express ...
... are central to understanding male infertility and could be ... according to a paper published by the journal ... how proteomics, a relatively new field focusing on the ... applied to infertility, helping identify which proteins in sperm ...
Cached Biology News:Researchers design artificial cells that could power medical implants 2Proteins in sperm unlock understanding of male infertility says new study 2
... is the experimental process of determining the ... automated DNA Sequencing is based on Sangers ... which allows cycle sequencing reactions. The resulting ... a capillary instrument controlled by a computer ...
...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... sequencing of plasmids and PCR amplicons. ... high performance sequencing pipeline which processes ... day. The key benefits we offer ... rapid turnaround, high sequencing pass rates ...
Biology Products: